Results 71 to 80 of about 415,260 (411)

Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT

American Journal of Hematology, Volume 98, Issue 1, Page 112-121, January 2023., 2023
Abstract Following the introduction of tyrosine kinase inhibitors (TKI), the number of patients undergoing allogeneic hematopoietic cell transplantation (allo‐HCT) for chronic phase (CP) chronic myeloid leukemia (CML) has dramatically decreased. Imatinib was the first TKI introduced to the clinical arena, predominantly utilized in the first line ...
Yves Chalandon, Giulia Sbianchi, Luuk Gras, Linda Koster, Jane Apperley, Jenny Byrne, Urpu Salmenniemi, Henrik Sengeloev, Mahmoud Aljurf, Grzegorz Helbig, Francesca Kinsella, Goda Choi, Péter Reményi, John A. Snowden, Marie Robin, Stig Lenhoff, Stephan Mielke, Jakob Passweg, Annoek E. C. Broers, Nicolaus Kröger, Zeynep Arzu Yegin, Sen Mui Tan, Patrick J. Hayden, Donal P. McLornan, Ibrahim Yakoub‐Agha, on behalf of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation (EBMT)   +25 more
wiley   +1 more source

Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy

Haematologica, 2015
Sex-mismatched hematopoietic cell transplantation is linked to increased graft-versus-host disease and mortality in myeloablative conditioning. Here we evaluated outcomes of 1,041 adult transplant recipients at two centers between 2006 and 2013 and ...
Hideki Nakasone, Mats Remberger, Lu Tian, Petter Brodin, Bita Sahaf, Fang Wu, Jonas Mattsson, Robert Lowsky, Robert Negrin, David B. Miklos, Everett Meyer   +10 more
doaj   +1 more source

Clonal Dominance and Transplantation Dynamics in Hematopoietic Stem Cell Compartments [PDF]

PLoS Comput Biol 13(10): e1005803 (2017), 2017
Hematopoietic stem cells in mammals are known to reside mostly in the bone marrow, but also transitively passage in small numbers in the blood. Experimental findings have suggested that they exist in a dynamic equilibrium, continuously migrating between these two compartments.
arxiv   +1 more source

Utilization of real‐world data in assessing treatment effectiveness for diffuse large B‐cell lymphoma

American Journal of Hematology, Volume 98, Issue 1, Page 180-192, January 2023., 2023
Abstract Direct comparisons of the effectiveness of the numerous novel therapies in the diffuse large B‐cell lymphoma (DLBCL) treatment landscape in a range of head‐to‐head randomized phase 3 trials would be time‐consuming and costly. Comparative effectiveness studies using real‐world data (RWD) represent a complementary approach.
Grzegorz Nowakowski, Matthew J. Maurer, James R. Cerhan, Debarshi Dey, Laurie H. Sehn   +4 more
wiley   +1 more source

Allogeneic Hematopoietic Stem Cell Transplantation in Myelofibrosis

Клиническая онкогематология, 2016
Background & Aims. At present, the allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only treatment option with curative potential in patients with myelofibrosis (MF), especially in intermediate and high risk categories.
MV Barabanshchikova, EV Morozova, VV Baikov, IM Barkhatov, NN Mamaev, SN Bondarenko, , AL Alyanskii, LS Zubarovskaya, BV Afanas’ev   +8 more
doaj   +1 more source

Graphene for Controlled and Accelerated Osteogenic Differentiation of Human Mesenchymal Stem Cells [PDF]

ACS Nano 5, 4670-4678 (2011), 2011
Modern tissue engineering strategies combine living cells and scaffold materials to develop biological substitutes that can restore tissue functions. Both natural and synthetic materials have been fabricated for transplantation of stem cells and their specific differentiation into muscles, bones and cartilages.
arxiv   +1 more source

Physiological conditions influencing regenerative potential of stem cells [PDF]

, 2016
Stem cells are being used in the treatment of cardivovascular diseases. Here, we review the physiologic and pathologic conditions that impact the regenerative potential of stem cells in the treatment of cardiovascular diseases which include the influence
Avitabile, Daniele, De Falco, Elena, Gambini, Elisa, Spaltro, Gabriella   +3 more
core   +1 more source

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

American Journal of Hematology, Volume 98, Issue 2, Page 272-281, February 2023., 2023
Abstract Patients with relapsed/refractory (R/R) higher‐risk myelodysplastic syndromes (MDS) have a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. There is no standard of care for patients after HMA therapy failure; hence, there is a critical need for effective therapeutic strategies.
Amer M. Zeidan, Uma Borate, Daniel A. Pollyea, Andrew M. Brunner, Fernando Roncolato, Jacqueline S. Garcia, Robin Filshie, Olatoyosi Odenike, Anne Marie Watson, Ravitharan Krishnadasan, Ashish Bajel, Kiran Naqvi, Jiuhong Zha, Wei‐Han Cheng, Ying Zhou, David Hoffman, Jason G. Harb, Jalaja Potluri, Guillermo Garcia‐Manero   +18 more
wiley   +1 more source

Prevention of transplant rejection can tolerance be achieved with immunosuppressive treatment? [PDF]

, 1996
Successful solid organ transplantation is generally attributed to the increasingly precise ability of drugs to control rejection. However, it was recently shown that a few donor haematolymphoid cells can survive for decades in recipients of successful ...
Delaney, CP, Demetris, AJ, Murase, N, Starzl, TE   +3 more
core   +1 more source

Leveraging current insights on IL‐10‐producing dendritic cells for developing effective immunotherapeutic approaches

FEBS Letters, EarlyView.
In vivo IL‐10 produced by tissue‐resident tolDC is involved in maintaining/inducing tolerance. Depending on the agent used for ex vivo tolDC generation, cells acquire common features but prime T cells towards anergy, FOXP3+ Tregs, or Tr1 cells according to the levels of IL‐10 produced. Ex vivo‐induced tolDC were administered to patients to re‐establish/
Konstantina Morali, Gloria Giacomello, Michela Vuono, Silvia Gregori   +3 more
wiley   +1 more source